Exagen (XGN) Revenue (2018 - 2026)

Exagen has reported Revenue for 9 years, with the latest figure at $17.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 11.67% year-over-year to $17.3 million; the trailing twelve-month figure through Mar 2026 stood at $68.4 million (up 20.55% YoY), and the FY2025 full-year result was $66.6 million, up 19.65% from the prior year.
• Revenue for Q1 2026 stood at $17.3 million, up from $16.6 million in the prior quarter.
• The five-year high for Revenue was $17.3 million in Q1 2026, with the low at $7.6 million in Q2 2022.
• Historically, Revenue has averaged $14.0 million across 5 years, with a median of $14.1 million in 2023.
• Annual changes were most pronounced in 2022 — Revenue tumbled 40.45% — and 2023, when it soared 85.87%.
• Exagen's Revenue stood at $12.8 million in 2022, then grew by 7.23% to $13.8 million in 2023, then declined by 0.8% to $13.7 million in 2024, then gained by 21.79% to $16.6 million in 2025, then rose by 4.06% to $17.3 million in 2026.
• The last three Revenue figures came in at $17.3 million (Q1 2026), $16.6 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.